Review ArticleSystematic Review
Open Access

Efficacy of carboplatin-based preoperative chemotherapy for triple-negative breast cancer

A meta-analysis of randomized controlled trials

Li-Yang Wang, Hua Xie, Hang Zhou, Wen-Xiu Yao, Xin Zhao and Yi Wang
Saudi Medical Journal January 2017, 38 (1) 18-23; DOI: https://doi.org/10.15537/smj.2017.1.14969

References

  1. ↵
    1. Jemal A,
    2. Bray F,
    3. Center MM,
    4. Ferlay J,
    5. Ward E,
    6. Forman D
    (2011) Global cancer statistics. CA Cancer J Clin 61:69–90.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Dent R,
    2. Trudeau M,
    3. Pritchard KI,
    4. Hanna WM,
    5. Kahn HK,
    6. Sawka CA,
    7. et al.
    (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15 Pt 1):4429–4434.
    OpenUrlAbstract/FREE Full Text
    1. Bauer KR,
    2. Brown M,
    3. Cress RD,
    4. Parise CA,
    5. Caggiano V
    (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109:1721–1728.
    OpenUrlCrossRefPubMedWeb of Science
    1. Gluz O,
    2. Liedtke C,
    3. Gottschalk N,
    4. Pusztai L,
    5. Nitz U,
    6. Harbeck N
    (2009) Triple-negative breast cancer--current status and future directions. Ann Oncol 20:1913–1927.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Haffty BG,
    2. Yang Q,
    3. Reiss M,
    4. Kearney T,
    5. Higgins SA,
    6. Weidhaas J,
    7. et al.
    (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24:5652–5657.
    OpenUrlAbstract/FREE Full Text
    1. Cleator S,
    2. Heller W,
    3. Coombes RC
    (2007) Triple-negative breast cancer: therapeutic options. Lancet Oncol 8:235–244.
    OpenUrlCrossRefPubMedWeb of Science
    1. Cheang MC,
    2. Voduc D,
    3. Bajdik C,
    4. Leung S,
    5. McKinney S,
    6. Chia SK,
    7. et al.
    (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14:1368–1376.
    OpenUrlAbstract/FREE Full Text
    1. Lin NU,
    2. Vanderplas A,
    3. Hughes ME,
    4. Theriault RL,
    5. Edge SB,
    6. Wong YN,
    7. et al.
    (2012) Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer 118:5463–5472.
    OpenUrlCrossRefPubMedWeb of Science
    1. Yuan N,
    2. Meng M,
    3. Liu C,
    4. Feng L,
    5. Hou L,
    6. Ning Q,
    7. et al.
    (2014) Clinical characteristics and prognostic analysis of triple-negative breast cancer patients. Mol Clin Oncol 2:245–251.
    OpenUrl
    1. Rakha EA,
    2. El-Sayed ME,
    3. Green AR,
    4. Lee AH,
    5. Robertson JF,
    6. Ellis IO
    (2007) Prognostic markers in triple-negative breast cancer. Cancer 109:25–32.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Tischkowitz M,
    2. Brunet JS,
    3. Bégin LR,
    4. Huntsman DG,
    5. Cheang MC,
    6. Akslen LA,
    7. et al.
    (2007) Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 7:134.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Chia S,
    2. Swain SM,
    3. Byrd DR,
    4. Mankoff DA
    (2008) Locally advanced and inflammatory breast cancer. J Clin Oncol 26:786–790.
    OpenUrlFREE Full Text
  13. ↵
    1. Fisher B,
    2. Bryant J,
    3. Wolmark N,
    4. Mamounas E,
    5. Brown A,
    6. Fisher ER,
    7. et al.
    (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672–2685.
    OpenUrlAbstract
  14. ↵
    1. Mieog JS,
    2. van der Hage JA,
    3. van de Velde CJ
    (2007) Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev 2:CD005002.
    OpenUrlPubMed
  15. ↵
    1. Liedtke C,
    2. Mazouni C,
    3. Hess KR,
    4. André F,
    5. Tordai A,
    6. Mejia JA,
    7. et al.
    (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275–1281.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Lee E,
    2. McKean-Cowdin R,
    3. Ma H,
    4. Spicer DV,
    5. Van Den Berg D,
    6. Bernstein L,
    7. et al.
    (2011) Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women. J Clin Oncol 29:4373–4380.
    OpenUrlAbstract/FREE Full Text
    1. Lakhani SR,
    2. Reis-Filho JS,
    3. Fulford L,
    4. Penault-Llorca F,
    5. van der Vijver M,
    6. Parry S,
    7. et al.
    (2005) Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 11:5175–5180.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Foulkes WD,
    2. Stefansson IM,
    3. Chappuis PO,
    4. Bégin LR,
    5. Goffin JR,
    6. Wong N,
    7. et al.
    (2003) Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95:1482–1485.
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    1. Alba E,
    2. Chacon JI,
    3. Lluch A,
    4. Anton A,
    5. Estevez L,
    6. Cirauqui B,
    7. et al.
    (2012) A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study. Breast Cancer Res Treat 136:487–493.
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    1. Sikov WM,
    2. Berry DA,
    3. Perou CM,
    4. Singh B,
    5. Cirrincione CT,
    6. Tolaney SM,
    7. et al.
    (2015) Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 33:13–21.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Von Minckwitz G,
    2. Schneeweiss A,
    3. Loibl S,
    4. Salat C,
    5. Denkert C,
    6. Rezai M,
    7. et al.
    (2014) Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto;GBG 66): a randomised phase 2 trial. Lancet Oncol 15:747–756.
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    1. Therasse P,
    2. Arbuck SG,
    3. Eisenhauer EA,
    4. Wanders J,
    5. Kaplan RS,
    6. Rubinstein L,
    7. et al.
    (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216.
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    1. Ando M,
    2. Yamauchi H,
    3. Aogi K,
    4. Shimizu S,
    5. Iwata H,
    6. Masuda N,
    7. et al.
    (2014) Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression. Breast Cancer Res Treat 145:401–409.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Zhang P,
    2. Yin Y,
    3. Xu B,
    4. Wang X,
    5. Zhang B,
    6. Li Q,
    7. et al.
    (2013) Carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for triple-negative breast cancer: a phase II clinical trial. San Antonio Breast Cancer Symposium, 73.
  25. ↵
    1. Petrelli F,
    2. Coinu A,
    3. Borgonovo K,
    4. Cabiddu M,
    5. Ghilardi M,
    6. Lonati V,
    7. et al.
    (2014) The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat 144:223–232.
    OpenUrlCrossRefPubMedWeb of Science
  26. ↵
    1. Chen XS,
    2. Yuan Y,
    3. Garfield DH,
    4. Wu J,
    5. Huang O,
    6. Shen KW
    (2014) Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis. PloS One 9:e108405.
    OpenUrl
  27. ↵
    1. Gerber B,
    2. Loibl S,
    3. Eidtmann H,
    4. Rezai M,
    5. Fasching PA,
    6. Tesch H,
    7. et al.
    (2013) Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers;results from the geparquinto study (GBG 44). Ann Oncol 24:2978–2984.
    OpenUrlCrossRefPubMedWeb of Science
  28. ↵
    1. Qi WX,
    2. Wang Q,
    3. Jiang YL,
    4. Sun YJ,
    5. Tang LN,
    6. He AN,
    7. et al.
    (2013) Overall survival benefits for combining targeted therapy as second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of published data. PloS One 8:e55637.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section